Jubilant Ingrevia reports 12% revenue growth in Q4 FY26 with ₹1,179 crore

Arunika Jain — Tue, 26 May 2026 09:28:21 +0000

Jubilant Ingrevia Limited has announced a robust financial performance for the fourth quarter of the fiscal year 2026, with total revenue reaching ₹1,179 crore, marking a 12% year-on-year increase. The company’s EBITDA for the quarter stood at ₹172 crore, reflecting an 11% growth compared to the same period last year.

The Board of Jubilant Ingrevia, during its meeting, approved the financial results for the quarter ended March 31, 2026. Commenting on the results, Chairman Shyam S Bhartia and Co-Chairman Hari S Bhartia highlighted the company’s effective handling of the Middle East crisis, which resulted in no force majeure and zero production loss. They also noted successful dispatches from the newly constructed Agro CDMO facility and the acquisition of Remidex to bolster the Human Nutrition business.

The Board has recommended a final dividend of ₹2.50 per share, bringing the total dividend for FY26 to ₹5 per share. Despite disruptions in the Middle East, the chemical industry’s demand remained resilient, with volumes continuing to grow and pricing firming up due to higher crude-linked costs.

In the Specialty Chemicals segment, revenue for Q4 FY26 was ₹516 crore, up 6% year-on-year, with EBITDA margins at approximately 27%. The Nutrition & Health Solutions segment reported a revenue of ₹230 crore, a 21% increase year-on-year, driven by strong demand for Niacinamide and a surge in Choline exports to Europe.

Jubilant Ingrevia’s Chief Executive Officer and Managing Director, Deepak Jain, emphasised the company’s strategic progress across all pillars, which has contributed to long-term growth despite global challenges. Jain noted that the company recorded its highest revenue in 14 quarters during Q4 FY26, with a 10% volume growth.

Looking forward, Jubilant Ingrevia expects continued growth in FY27, led by Specialty Chemicals and Nutrition, along with a recovery in Acetyls. The company is also progressing well with the construction of the Gajraula Multi-Purpose Plant, which will further strengthen its CDMO growth roadmap.

Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).

Deepak Jain | Business Upturn

Jubilant Ingrevia reports 12% revenue growth in Q4 FY26 with ₹1,179 crore